Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Qyuns Therapeutics / Equity Capital Markets

<ul>
<li>Qyuns Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$ 100m via a Hong Kong listing.</li>
<li>In this note, we examine the company's core products, namely QX002N, an IL-17A antibody, and QX005N, an IL-4Rα antibody. We also look at the company's management and pre-IPO investors.</li>
<li>We are of mixed views for its two core products. We also think the management and pre-IPO investors are of mediocre quality.</li>
</ul>


Qyuns Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$ 100m via a Hong Kong listing.
In this note, we examine the company's core products, namely QX002N, an IL-17A antibody, and QX005N, an IL-4Rα antibody. We also look at the company's management and pre-IPO investors.
We are of mixed views for its two core products. We also think the management and pre-IPO investors are of mediocre quality.


Qyuns Therapeutics (荃信生物) Pre-IPO: Mixed View on Two Core Products

China

Qyuns Therapeutics Co., Ltd. develops and distributes medical drugs. The Company produces immune disease antibody drugs, monoclonal antibody drugs, and other products. Qyuns Therapeutics also operates import and export businesses.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Qyuns Therapeutics (1822972D CH)

Qyuns Therapeutics (荃信生物) Pre-IPO: Mixed View on Two Core Products

In this note, we look at fundamentals of Qyuns Therapeutics. We examined the two core products, QX002N and QX005N. We have mixed view on its...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)